Exclusive from BIO-Europe 2015: Interview of Peter Llewellyn-Davies, CFO at Medigene, Munich-based Immunotherapy Biotech

peter Llewellyn Davies medigene interview

This is the third interview we publish from BIO (yes, we are working hard). It comes after the interview of Simon Moroney, CEO of MorphoSys and Jane Dancer, CBO of F-star.

medigene-logo-frontMedigene is another big/famous Biotech company of Munich, Germany. It was founded over 20 years ago and is now specialised in cell-based therapies. It counts roughly 70 employees and has a market cap of 150 million euros. Peter Llewellyn-Davies has previously worked as CFO of Wilex AG and been in the board of ImmunoCore (the UK Biotech which raised $330 million in a private round!!)

It was very exciting to meet Peter and interviewing him on Medigene’s dendritic cells vaccines, its TCR program as well as its financial situation.

Check it out:

Bonus – Medigene did a great animation video on how its TCR works. Worth checking out too:

Explore other topics: CancerGermanyImmunotherapyMedigene

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.

Suggested Articles

Show More